Comparison of EFGR mutation status in paired pre- and post-chemotherapy serum for advanced pulmonary adenocarcinoma

Chinese Journal of Lung Cancer

Volumn 14, Issue 2, 2011, Pages 127-131

  Han, Rubing ^a   Zhong, Wei ^a   Zhao, Jing ^a   Zhang, Li ^a   Xia, Ying ^a   Wang, Han ^a   Li, Longyun ^a   Wang, Mengzhao ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Chemotherapy; Lung neoplasms; Mutation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MAGNETIC NANOPARTICLE; PROTEIN KINASE INHIBITOR;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DNA EXTRACTION; HUMAN; LUNG ADENOCARCINOMA; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TREATMENT RESPONSE; ADENOCARCINOMA; ADULT; AGED; BLOOD; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; MALE; MIDDLE AGED; MUTATION; RADIATION EXPOSURE;

ADENOCARCINOMA; ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79953901447     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2011.02.04     Document Type: Article

References (14)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350(21): 2129-2139.
2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676): 1497-1500.
3. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol, 2006, 24 (31): 5034-5042.
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005, 353(2): 123-132.
5. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol, 2010, 28(5): 744-752.
6. Rosell R, Moran T, Queralt C, et al. Screening for epiderminal growth factor receptor mutations in lung cancer. N Engl J Med, 2009, 361(10): 958-967.
7. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361(10): 947-957.
8. Kobayashi K, Inoue A, Maemondo M, et al. First-line gefitinib versus firstline chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in nonsmall cell lung cancer (NSCLC) patients (pts) with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group. J Clin Oncol, 2009, 15S(27): abstr 8016.
9. Sozzi G, Conte D, Leon M, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol, 2003, 21(21): 3902-3908.
10. Kimura H, Suminoe M, Kasahara K, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer, 2007, 97(6): 778-784.
11. Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stage IIIB to IV non-small-cell lung cancer. J Chin Oncol, 2009, 27(16): 2653-2659.
12. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11(2): 121-128.
13. Gow CH, Chang YL, Hsu YC, et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naïve non-small-cell lung cancer. Ann Oncol, 2008, 20(4): 696-702.
14. Chin TM, Quinlan MP, Singh A, et al. Reduced erlotinib sensitivity of epidermal growth factor receptor-mutant non-small-cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. Clin Cancer Res, 2008, 14(21): 6867-6876.